Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Is annual screening by fecal immunochemical test necessary after a recent colonoscopy?

  Yutaka Okagawa, Tetsuya Sumiyoshi, Kota Hanada, Sota Hirokawa, Yusuke Tomita, Masahiro Yoshida, Takeyoshi Minagawa, Kohtaro Morita, Kei Yane, Hideyuki Ihara, Michiaki Hirayama, Hitoshi Kondo

  DEN open   5 ( 1 ) e385  2025.04  [International journal]

  　View Summary

  OBJECTIVE: The population-based colorectal cancer screening guidelines in Japan recommend an annual fecal immunochemical test (FIT). However, there is no consensus on the need for annual FIT screening for patients who recently performed a total colonoscopy (TCS). Therefore, we evaluated the repeated TCS results for patients with positive FIT after a recent TCS to assess the necessity of an annual FIT. METHODS: We reviewed patients with positive FIT in opportunistic screening from April 2017 to March 2022. The patients were divided into two groups: those who had undergone TCS within the previous 5 years (previous TCS group) and those who had not (non-previous TCS group). We compared the detection rates of advanced neoplasia and colorectal cancer between the two groups. RESULTS: Of 671 patients, 151 had received TCS within 5 years and 520 had not. The detection rates of advanced neoplasia in the previous TCS and non-previous TCS groups were 4.6% and 12.1%, respectively (p < 0.01), and the colorectal cancer detection rates were 0.7% and 1.5%, respectively (no significant difference). The adenoma detection rates were 33.8% in the previous TCS group and 40.0% in the non-previous TCS group (no significant difference). CONCLUSIONS: Only a few patients were diagnosed with advanced neoplasia among the patients with FIT positive after a recent TCS. For patients with adenomatous lesions on previous TCS, repeated TCS should be performed according to the surveillance program without an annual FIT. The need for an annual FIT for patients without adenomatous lesions on previous TCS should be prospectively assessed in the future.

  DOI PubMed

• Clinicopathological features of early-onset colorectal cancer in Japanese patients: a single-center retrospective study.

  Yutaka Okagawa, Keita Seto, Koki Yoshida, Kota Hanada, Sota Hirokawa, Yusuke Tomita, Kaho Tokuchi, Takeyoshi Minagawa, Kohtaro Morita, Kei Yane, Michiaki Hirayama, Hitoshi Kondo, Tetsuya Sumiyoshi

  BMC gastroenterology   25 ( 1 ) 156 - 156  2025.03  [International journal]

  　View Summary

  BACKGROUND: The incidence of early-onset colorectal cancer (EoCRC), defined as CRC diagnosed at < 50 years of age, is increasing globally. However, only a few studies are reported from Japan, and the clinicopathological features of EoCRC in Japanese patients remain unknown. METHODS: We retrospectively investigated consecutive Japanese patients who were pathologically diagnosed with invasive CRC at our hospital from January 2015 to December 2021. Patients were categorized into those who were diagnosed with CRC at < 50 years (early-onset group) and ≥ 50 years (late-onset group) of age. We compared the clinicopathological findings between the two groups. RESULTS: The analysis included 731 patients. EoCRC was diagnosed in 46 patients (6.3% of all patients). Of them, 41.3% demonstrated a positive fecal immunochemical test (FIT) for CRC screening as a diagnostic opportunity, which was significantly higher than that in the late-onset group (p = 0.032). Rectal cancer was significantly more prevalent in the early-onset group compared to the late-onset group (45.7% vs. 26.4%, p < 001). No significant difference in the rate of clinical stage at presentation was found between the two groups. Furthermore, patients with positive FIT were more likely diagnosed at an earlier stage. CONCLUSIONS: EoCRC among Japanese patients tends to occur on the rectum and is more frequently diagnosed with FIT screening compared to late-onset CRC. Patients with advanced stage were diagnosed by symptoms, indicating the usefulness of FIT screening in diagnosing EoCRC at an early stage.

  DOI PubMed

• Usefulness of endoscopic ultrasound-guided transhepatic biliary drainage with a 22-gauge fine-needle aspiration needle and 0.018-inch guidewire in the procedure's induction phase.

  Kei Yane, Masahiro Yoshida, Takayuki Imagawa, Kotaro Morita, Hideyuki Ihara, Kota Hanada, Sota Hirokawa, Yusuke Tomita, Takeyoshi Minagawa, Yutaka Okagawa, Tetsuya Sumiyoshi, Michiaki Hirayama, Hitoshi Kondo

  DEN open   4 ( 1 ) e297  2024.04  [International journal]

  　View Summary

  Endoscopic ultrasound (EUS)-guided transhepatic biliary drainage is usually performed with a 19-gauge fine-needle aspiration (FNA) needle and a 0.025-inch guidewire. The combination of a 22-gauge FNA needle and a 0.018-inch guidewire is reported to be effective as a rescue option when the bile duct diameter is small or technically challenging. Experts in EUS-guided transhepatic biliary drainage have reported that bile duct puncture with a 19-gauge FNA needle is possible in most cases, but is not easy to reproduce by endoscopists with less experience in EUS-guided transhepatic biliary drainage. We investigated the usefulness of EUS-guided transhepatic biliary drainage using a 22-gauge FNA needle and a 0.018-inch guidewire during the procedure's induction phase. Consecutive patients who underwent EUS-guided transhepatic biliary drainage at our institution from March 2021 to May 2023 were evaluated, and 37 were included. Biliary drainage was performed for malignant bile duct stricture in 36 patients and choledocholithiasis in one patient. The median target bile duct diameter was 4.5 mm (2.5-9.4). Biliary access, fistula dilation, and stent placement were successful in the 37 patients (100%). The median procedure time was 35 min (16-125). Adverse events occurred in four (10.8%) patients. EUS-guided transhepatic biliary drainage using a 22-gauge FNA needle and a 0.018-inch guidewire is a useful and promising option for endoscopists with limited experience in EUS-guided transhepatic biliary drainage in the procedure's induction phase.

  DOI PubMed

• A novel technique using a multiloop traction device for colonic diverticular bleeding.

  Yutaka Okagawa, Ryoji Fujii, Tetsuya Sumiyoshi, Mai Fukuda, Yusuke Tomita, Takeyoshi Minagawa, Hitoshi Kondo

  Endoscopy   55 ( S 01 ) E47-E48  2023.12  [International journal]

  DOI PubMed

• Clinical factors associated with acute abdominal symptoms induced by gastric anisakiasis: a multicenter retrospective cohort study.

  Yutaka Okagawa, Tetsuya Sumiyoshi, Takayuki Imagawa, Hiroya Sakano, Fumito Tamura, Yohei Arihara, Yusuke Kanari, Akira Sakurada, Shutaro Oiwa, Takashi Jin, Yusuke Tomita, Shinya Minami, Hiroyuki Hisai, Hirohito Muramatsu, Shinichi Katsuki, Masahiro Maeda, Hitoshi Kondo

  BMC gastroenterology   23 ( 1 ) 243 - 243  2023.07  [International journal]

  　View Summary

  BACKGROUND: Gastric anisakiasis typically causes severe abdominal symptoms; however, we incidentally detected asymptomatic gastric anisakiasis cases during esophagogastroduodenoscopy. The factors associated with developing acute abdominal symptoms induced by gastric anisakiasis remain unclear. Therefore, this study aimed to investigate the clinical factors associated with abdominal symptoms of gastric anisakiasis by comparing symptomatic and asymptomatic cases. METHODS: This was a retrospective cohort study involving 264 patients diagnosed with gastric anisakiasis at nine hospitals in Japan between October 2015 and October 2021. We analyzed patients' medical records and endoscopic images and compared the clinical factors between the symptomatic and asymptomatic groups. RESULTS: One hundred sixty-five patients (77.8%) were diagnosed with abdominal symptoms, whereas 47 (22.2%) were asymptomatic. Older age, male sex, diabetes mellitus, gastric mucosal atrophy, and gastric mucosal atrophy of the Anisakis penetrating area were significantly more common in the asymptomatic group than in the symptomatic group. Multivariate analysis revealed that age (p = 0.007), sex (p = 0.017), and presence or absence of mucosal atrophy (p = 0.033) were independent factors for the occurrence of acute abdominal symptoms. In addition, cases that were Helicobacter pylori naïve, with an elevation of white blood cells, or without an elevation of eosinophils were more common in the symptomatic group than in the asymptomatic group. CONCLUSIONS: Age, sex, and presence or absence of gastric mucosal atrophy were the clinical factors associated with the occurrence of acute abdominal symptoms. Older and male patients and those with gastric mucosal atrophy were less likely to show abdominal symptoms. The mechanisms of the occurrence of symptoms induced by gastric anisakiasis remain unclear; however, our results will help clarify this issue in the future.

  DOI PubMed

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 特集 胃疾患アトラス 改訂版 各論 Ⅰ. 隆起を呈する病変 1. 上皮性･非腫瘍性隆起病変 A. 亜有茎性･有茎性隆起 胃若年性ポリープ

  岡川 泰, 住吉 徹哉, 近藤 仁

  消化器内視鏡 ( 東京医学社 )  34 ( 13 ) 56 - 57  2022.10

  DOI

• 早期胃癌に対する内視鏡治療の現状と課題—第69回共済医学会特集 ; 教育講演

  住吉 徹哉, 魚住 健志, 飯田 怜一, 吉田 将大, 櫻田 晃, 藤井 亮爾, 皆川 武慶, 岡川 泰, 森田 康太郎, 矢根 圭, 庵原 秀之, 平山 眞章, 近藤 仁

  共済医報 ( 東京 : 国家公務員共済組合連合会共済医学会 )  70 ( 2 ) 98 - 105  2021.05

  CiNii

• 今月の主題 消化管疾患AI診断の現状 主題 大腸疾患におけるAI診断

  斎藤 豊, 山田 真善, 坂本 琢, 高丸 博之, 関口 正宇, 松田 尚久, 岡川 泰, 阿部 清一郎, 水口 康彦, 春日 健吾, 江郷 茉衣, 張 萌琳

  胃と腸 ( 株式会社医学書院 )  56 ( 4 ) 462 - 471  2021.04

  DOI DOI2

• 特集 上部消化管腫瘍における先進的内視鏡治療の進歩 1 .前癌病変,早期癌に対する内視鏡治療の種類と適応(2)胃

  岡川 泰, 小田 一郎, 阿部 清一郎, 野中 哲, 鈴木 晴久, 吉永 繁高

  臨床消化器内科 ( 日本メディカルセンター )  36 ( 1 ) 14 - 23  2020.12

  DOI

• ANTERIOR ARYTENOID DISLOCATION THAT DEVELOPED AFTER ESOPHAGOGASTRODUODENOSCOPY: A CASE REPORT

  UOZUMI Takeshi, SUMIYOSHI Tetsuya, YAMANASHI Kana, FUJII Ryoji, MINAGAWA Takeyoshi, OKAGAWA Yutaka, IHARA Hideyuki, HIRAYAMA Michiaki, KONDO Hitoshi

  GASTROENTEROLOGICAL ENDOSCOPY ( Japan Gastroenterological Endoscopy Society )  62 ( 10 ) 2269 - 2273  2020

  　View Summary

  A 72-year-old man visited our hospital to undergo esophagogastroduodenoscopy (EGD) for epigastric pain. Following EGD, he developed hoarseness, which persisted even after four days; therefore, we referred him to an otolaryngologist. Laryngoscopy revealed anterior dislocation of the left arytenoid cartilage, with a flaccid and shortened left vocal cord. Maximum phonation time was remarkably reduced to 3 seconds. Computed tomography findings were normal. Arytenoid dislocation caused by EGD was diagnosed. The patient underwent noninvasive reduction under general anesthesia.

  DOI CiNii

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• FUTを標的とした進行大腸癌に対する抗EMT療法の開発

  基盤研究(C)

  Project Year :

  2015.04

  -

  2016.03

   

  瀧本 理修, 加藤 淳二, 大須賀 崇裕, 岡川 泰, 佐藤 康史

  　View Summary

  大腸癌細胞の転移・浸潤には上皮間葉移行（EMT）が関与している．再発転移進行大腸癌の長期予後を改善するためには，悪性形質の一つである転移・浸潤を克服することが極めて重要である．そこで，申請者らは新規治療法の開発のために，がん細胞の転移を抑制する抗EMT療法を考案し基礎検討を実施した．申請者らはこれまでのpreliminaryな検討から，EMT亢進の機序として増殖因子受容体の糖鎖修飾が重要な役割を果たしていることを見出している．そこで，この糖鎖修飾を担う酵素の発現を各種大腸がん細胞株で検討し，これらの細胞株におけるEMTと糖鎖修飾酵素の関連性を比較した．その結果，糖鎖修飾酵素の中でFucosyltransferase（FUT）の発現が亢進している細胞株ではEMTも高まっていることが確認された．そこで，この糖鎖修飾分子を標的とした抗転移分子標的療法の可能性を検討した．その結果，FUT3, FUT6を抑制することによりEMT関連誘導分子の発現抑制とEMTの低下，浸潤能および遊走能が低下することが明らかとなった． 現在，糖鎖修飾酵素を抑制するsiRNAを作製し，その効率を検討した上でEMTに対する影響を検討する予定である．その上で，我々が開発した糖鎖修飾リポソームにFUTに対するsiRNAを搭載することで腫瘍特異性を高め，大腸ガン細胞を標的とすることで有害事象を軽減した抗転移抑制療法として臨床応用に向けた基礎的な検討を行い有用性を検証したい．

• Development of a novel pancreatic cancer rapid diagnostic method by the fucosyltransferases mRNA detection in peripheral blood

  Grant-in-Aid for Challenging Exploratory Research

  Project Year :

  2014.04

  -

  2016.03

   

  Kato Junji, TAKIMONO Risyu, Osuga Takahiro, Okagawa Yutaka

  　View Summary

  It is very useful for the diagnosis of cancer and monitoring of the curative effect if we can rapidly measure protein and a nucleic acid from cancer cell in the peripheral blood with high sensitivity. Numerous fucosylated antigens in sera like CA19-9 serve as tumor markers for pancreatic cancer. We developed a novel pancreatic cancer rapid diagnostic method by the fucosyltransferases mRNA detection in peripheral blood using Droplet Digital PCR (ddPCR).